Evidence-Based Psychosocial Treatments for Adolescent Substance Abuse / Holly BARRETT WALDRON in Journal of Clinical Child & Adolescent Psychology, 37-1 (January-March 2008)  

Public ISBD [article]  inJournal of Clinical Child & Adolescent Psychology > 37-1 (January-March 2008) . - p.238-261 Titre : Evidence-Based Psychosocial Treatments for Adolescent Substance Abuse Type de document : Texte imprimé et/ou numérique Auteurs : Holly BARRETT WALDRON, Auteur ; Charles TURNER, Auteur Année de publication : 2008 Article en page(s) : p.238-261 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : This review synthesized findings from 17 studies since 1998 regarding evaluation of outpatient treatments for adolescent substance abuse. These studies represented systematic design advances in adolescent clinical trial science. The research examined 46 different intervention conditions with a total sample of 2,307 adolescents. The sample included 7 individual cognitive behavior therapy (CBT) replications (n = 367), 13 group CBT replications (n = 771), 17 family therapy replications (n = 850) and 9 minimal treatment control conditions (n = 319). The total sample was composed of approximately 75% males, and the ethnic/racial distribution was approximately 45% White, 25% Hispanic, 25% African American, and 5% other groups. Meta-analysis was used to evaluate within-group effect sizes as well as differences between active treatment conditions and the minimal treatment control conditions. Methodological rigor of studies was classified using Nathan and Gorman (2002) criteria, and treatments were classified using criteria for well-established and probably efficacious interventions based on Chambless et al. (1996). Three treatment approaches, multidimensional family therapy, functional family therapy, and group CBT emerged as well-established models for substance abuse treatment. However, a number of other models are probably efficacious, and none of the treatment approaches appeared to be clearly superior to any others in terms of treatment effectiveness for adolescent substance abuse. En ligne : http://dx.doi.org/10.1080/15374410701820133 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=399 [article] Evidence-Based Psychosocial Treatments for Adolescent Substance Abuse [Texte imprimé et/ou numérique] / Holly BARRETT WALDRON, Auteur ; Charles TURNER, Auteur . - 2008 . - p.238-261. Langues : Anglais (eng) in Journal of Clinical Child & Adolescent Psychology > 37-1 (January-March 2008) . - p.238-261 Index. décimale : PER Périodiques Résumé : This review synthesized findings from 17 studies since 1998 regarding evaluation of outpatient treatments for adolescent substance abuse. These studies represented systematic design advances in adolescent clinical trial science. The research examined 46 different intervention conditions with a total sample of 2,307 adolescents. The sample included 7 individual cognitive behavior therapy (CBT) replications (n = 367), 13 group CBT replications (n = 771), 17 family therapy replications (n = 850) and 9 minimal treatment control conditions (n = 319). The total sample was composed of approximately 75% males, and the ethnic/racial distribution was approximately 45% White, 25% Hispanic, 25% African American, and 5% other groups. Meta-analysis was used to evaluate within-group effect sizes as well as differences between active treatment conditions and the minimal treatment control conditions. Methodological rigor of studies was classified using Nathan and Gorman (2002) criteria, and treatments were classified using criteria for well-established and probably efficacious interventions based on Chambless et al. (1996). Three treatment approaches, multidimensional family therapy, functional family therapy, and group CBT emerged as well-established models for substance abuse treatment. However, a number of other models are probably efficacious, and none of the treatment approaches appeared to be clearly superior to any others in terms of treatment effectiveness for adolescent substance abuse. En ligne : http://dx.doi.org/10.1080/15374410701820133 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=399

Gut Permeability in Autism Spectrum Disorders / Neil R. DALTON in Autism Research, 7-3 (June 2014)  

Public ISBD [article]  inAutism Research > 7-3 (June 2014) . - p.305-313 Titre : Gut Permeability in Autism Spectrum Disorders Type de document : Texte imprimé et/ou numérique Auteurs : Neil R. DALTON, Auteur ; Susie CHANDLER, Auteur ; Charles TURNER, Auteur ; Tony CHARMAN, Auteur ; Andrew PICKLES, Auteur ; Tom LOUCAS, Auteur ; Emily SIMONOFF, Auteur ; Peter SULLIVAN, Auteur ; Gillian BAIRD, Auteur Article en page(s) : p.305-313 Langues : Anglais (eng) Mots-clés : autism  autism spectrum disorders  gut permeability  lactulose/mannitol ratio Index. décimale : PER Périodiques Résumé : Objective To test whether gut permeability is increased in autism spectrum disorders (ASD) by evaluating gut permeability in a population-derived cohort of children with ASD compared with age- and intelligence quotient-matched controls without ASD but with special educational needs (SEN). Patients and Methods One hundred thirty-three children aged 10–14 years, 103 with ASD and 30 with SEN, were given an oral test dose of mannitol and lactulose and urine collected for 6?hr. Gut permeability was assessed by measuring the urine lactulose/mannitol (L/M) recovery ratio by electrospray mass spectrometry-mass spectrometry. The ASD group was subcategorized for comparison into those without (n?=?83) and with (n?=?20) regression. Results There was no significant difference in L/M recovery ratio (mean (95% confidence interval)) between the groups with ASD: 0.015 (0.013–0.018), and SEN: 0.014 (0.009–0.019), nor in lactulose, mannitol, or creatinine recovery. No significant differences were observed in any parameter for the regressed versus non-regressed ASD groups. Results were consistent with previously published normal ranges. Eleven children (9/103?=?8.7% ASD and 2/30?=?6.7% SEN) had L/M recovery ratio ?0.03 (the accepted normal range cut-off), of whom two (one ASD and one SEN) had more definitely pathological L/M recovery ratios ?0.04. Conclusion There is no statistically significant group difference in small intestine permeability in a population cohort-derived group of children with ASD compared with a control group with SEN. Of the two children (one ASD and one SEN) with an L/M recovery ratio of ?0.04, one had undiagnosed asymptomatic celiac disease (ASD) and the other (SEN) past extensive surgery for gastroschisis. Autism Res 2014, 7: 305–313. © 2013 International Society for Autism Research, Wiley Periodicals, Inc. En ligne : http://dx.doi.org/10.1002/aur.1350 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=235 [article] Gut Permeability in Autism Spectrum Disorders [Texte imprimé et/ou numérique] / Neil R. DALTON, Auteur ; Susie CHANDLER, Auteur ; Charles TURNER, Auteur ; Tony CHARMAN, Auteur ; Andrew PICKLES, Auteur ; Tom LOUCAS, Auteur ; Emily SIMONOFF, Auteur ; Peter SULLIVAN, Auteur ; Gillian BAIRD, Auteur . - p.305-313. Langues : Anglais (eng) in Autism Research > 7-3 (June 2014) . - p.305-313 Mots-clés : autism  autism spectrum disorders  gut permeability  lactulose/mannitol ratio Index. décimale : PER Périodiques Résumé : Objective To test whether gut permeability is increased in autism spectrum disorders (ASD) by evaluating gut permeability in a population-derived cohort of children with ASD compared with age- and intelligence quotient-matched controls without ASD but with special educational needs (SEN). Patients and Methods One hundred thirty-three children aged 10–14 years, 103 with ASD and 30 with SEN, were given an oral test dose of mannitol and lactulose and urine collected for 6?hr. Gut permeability was assessed by measuring the urine lactulose/mannitol (L/M) recovery ratio by electrospray mass spectrometry-mass spectrometry. The ASD group was subcategorized for comparison into those without (n?=?83) and with (n?=?20) regression. Results There was no significant difference in L/M recovery ratio (mean (95% confidence interval)) between the groups with ASD: 0.015 (0.013–0.018), and SEN: 0.014 (0.009–0.019), nor in lactulose, mannitol, or creatinine recovery. No significant differences were observed in any parameter for the regressed versus non-regressed ASD groups. Results were consistent with previously published normal ranges. Eleven children (9/103?=?8.7% ASD and 2/30?=?6.7% SEN) had L/M recovery ratio ?0.03 (the accepted normal range cut-off), of whom two (one ASD and one SEN) had more definitely pathological L/M recovery ratios ?0.04. Conclusion There is no statistically significant group difference in small intestine permeability in a population cohort-derived group of children with ASD compared with a control group with SEN. Of the two children (one ASD and one SEN) with an L/M recovery ratio of ?0.04, one had undiagnosed asymptomatic celiac disease (ASD) and the other (SEN) past extensive surgery for gastroschisis. Autism Res 2014, 7: 305–313. © 2013 International Society for Autism Research, Wiley Periodicals, Inc. En ligne : http://dx.doi.org/10.1002/aur.1350 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=235

Measurement of urine indolylacroylglycine is not useful in the diagnosis or dietary management of autism / Neil R. DALTON in Autism Research, 10-3 (March 2017)  

Public ISBD [article]  inAutism Research > 10-3 (March 2017) . - p.408-413 Titre : Measurement of urine indolylacroylglycine is not useful in the diagnosis or dietary management of autism Type de document : Texte imprimé et/ou numérique Auteurs : Neil R. DALTON, Auteur ; Susie CHANDLER, Auteur ; Charles TURNER, Auteur ; Tony CHARMAN, Auteur ; Andrew PICKLES, Auteur ; Emily SIMONOFF, Auteur ; Gillian BAIRD, Auteur Article en page(s) : p.408-413 Langues : Anglais (eng) Mots-clés : autism  indoleacroylglycine  gastrointestinal  regression Index. décimale : PER Périodiques Résumé : To measure urine indolylacroylglycine (IAG) excretion using the IAG:creatinine ratio in children with autism spectrum disorder (ASD) compared with two groups of age matched controls, one with special needs but without ASD (SEN) and one typically developing (TD) and in subgroups with/without current gastrointestinal problems and ASD with and without regression. IAG:creatinine ratio was measured in the urine of 279 children aged 10–14 years: 129 children with ASD (28 with and 101 without regression), 62 SEN controls and 88 TD controls. The prevalence of gastro-intestinal symptoms (GIS) was recorded. No differences were found in the urine IAG:creatinine ratio among groups ASD, TD and SEN; nor in the ASD groups with/without regression, nor in those with/without GIS. This study finds no evidence of increased urine IAG excretion in children with ASD, with or without GIS or with or without regression. Urinary IAG measurements in children with ASD offer no support for increased presence of neuroactive peptides proposed to result from increased gut permeability. We found measurement of urinary IAG to have no value in the diagnosis of autism or in the dietary management of children with ASD. En ligne : http://dx.doi.org/10.1002/aur.1688 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=304 [article] Measurement of urine indolylacroylglycine is not useful in the diagnosis or dietary management of autism [Texte imprimé et/ou numérique] / Neil R. DALTON, Auteur ; Susie CHANDLER, Auteur ; Charles TURNER, Auteur ; Tony CHARMAN, Auteur ; Andrew PICKLES, Auteur ; Emily SIMONOFF, Auteur ; Gillian BAIRD, Auteur . - p.408-413. Langues : Anglais (eng) in Autism Research > 10-3 (March 2017) . - p.408-413 Mots-clés : autism  indoleacroylglycine  gastrointestinal  regression Index. décimale : PER Périodiques Résumé : To measure urine indolylacroylglycine (IAG) excretion using the IAG:creatinine ratio in children with autism spectrum disorder (ASD) compared with two groups of age matched controls, one with special needs but without ASD (SEN) and one typically developing (TD) and in subgroups with/without current gastrointestinal problems and ASD with and without regression. IAG:creatinine ratio was measured in the urine of 279 children aged 10–14 years: 129 children with ASD (28 with and 101 without regression), 62 SEN controls and 88 TD controls. The prevalence of gastro-intestinal symptoms (GIS) was recorded. No differences were found in the urine IAG:creatinine ratio among groups ASD, TD and SEN; nor in the ASD groups with/without regression, nor in those with/without GIS. This study finds no evidence of increased urine IAG excretion in children with ASD, with or without GIS or with or without regression. Urinary IAG measurements in children with ASD offer no support for increased presence of neuroactive peptides proposed to result from increased gut permeability. We found measurement of urinary IAG to have no value in the diagnosis of autism or in the dietary management of children with ASD. En ligne : http://dx.doi.org/10.1002/aur.1688 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=304

---

1 (1 - 3 / 3)